CoChat

Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis

Open access
Ruzehaji, Nadira, Frantz, Camelia, Ponsoye, Matthieu, Avouac, Jerome, Pezet, Sonia, Guilbert, Thomas, Luccarini, Jean-Michel, Broqua, Pierre, Junien, Jean-Louis, Allanore, Yannick · 2016 · Annals of the Rheumatic Diseases
Cited by 101

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The pathogenesis of systemic sclerosis (SSc) involves a distinctive triad of autoimmune, vascular and inflammatory alterations resulting in fibrosis. Evidence suggests that peroxisome proliferator-activated receptors (PPARs) play an important role in SSc-related fibrosis and their agonists may become effective therapeutic targets. OBJECTIVE: To determine the expression of PPARs in human fibrotic skin and investigate the effects of IVA337, a pan PPAR agonist, in in vitro and in vivo models of fibrosis. METHODS: The antifibrotic effects of IVA337 were studied using a bleomycin-induced mouse model of dermal fibrosis. The in vivo effect of IVA337 on wound closure and inflammation were studied using an excisional model of wound healing. RESULTS: Low levels of PPARα and PPARγ were detected in the skin of patients with SSc compared with controls. In mice, IVA337 was associated with decreased extracellular matrix (ECM) deposition and reduced expression of phosphorylated SMAD2/3-intracellular effector of transforming growth factor (TGF)-β1. Although the antifibrotic effect of pan PPAR was similar to that of PPARγ agonist alone, a significant downregulation of several markers of inflammation was associated with IVA337. Despite its anti-inflammatory and antifibrotic properties, IVA337 did not interfere with wound closure. In vitro effects of IVA337 included attenuation of transcription of ECM genes and alteration of canonical and non-canonical TGF-β signalling pathways. CONCLUSIONS: These findings indicate that simultaneous activation of all three PPAR isoforms exerts a dampening effect on inflammation and fibrosis, making IVA337 a potentially effective therapeutic candidate in the treatment of fibrotic diseases including SSc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2015-208029

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 101

Metadata

Authors
Ruzehaji, N., Frantz, C., Ponsoye, M., Avouac, J., Pezet, S., Guilbert, T., Luccarini, J.-M., Broqua, P., Junien, J.-L., & Allanore, Y.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2016-12
Volume
75
Issue
12
Pages
2175-2183
ISSN
0003-4967 (ISSN-L)
OpenAlex
W2338295645
Cited by
101
References
4
FWCI
9.64
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis. https://app.cochat.ai/papers/10.1136/annrheumdis-2015-208029
The paper
Ruzehaji, N., Frantz, C., Ponsoye, M., Avouac, J., Pezet, S., Guilbert, T., Luccarini, J.-M., Broqua, P., Junien, J.-L., & Allanore, Y. (2016). Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2015-208029

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.